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Introduction 
In Lynch / HNPCC syndrome tumours that 
have lost mismatch repair (MMR) function, 
immunohistochemistry (IHC) can be used to 
show abnormal MMR protein expression.  
Lynch / HNPCC sufferers inherit one 
germline mutant MMR allele and one 
normal, wild-type MMR allele.  During 
tumour formation, the normal allele is 
inactivated by mutation or loss, thus 
leaving no expression of functional alleles.  
MMR abnormal expression in Lynch / 
HNPCC tumours may thus be detected by 
IHC in two patterns: either complete loss of 
expression (when there is no expression of 
that MMR protein or only expression of a 
truncated protein to which the antibody 
does not bind), or patchy/weak expression 
(if the mutation generates a prematurely 
truncated but variably stable protein, or a 
protein with alterations to the epitope 
recognised by the antibody, e.g. missense 
mutation). It is important to realise, 
however, that a small proportion, perhaps 
5-20% of Lynch / HNPCC-related tumours 
do not exhibit any abnormality on analysis 
by IHC even though they have lost MMR 
function, as manifested by microsatellite 
instability (MSI) and this may be due to 
mutations that functionally inactivate the 
MMR protein but allow its expression as a 
stable protein with nuclear localisation and 
intact epitope. 
 
IHC Recommendations 
Where possible, IHC should be carried out 
using an automated staining machine.  
Manual IHC is prone to significant variation, 
both within and between batches.  
Automated immunostaining generates 
more consistent and reproducible staining 
patterns.  
Use of 4 MMR antibodies (MSH2, MLH1, 
MSH6 & PMS2) is recommended over the 
use of only 2 MMR antibodies (MSH2 & 
MLH1), as there is a heterodimeric 
association of  proteins, such that 
abnormality of MSH2 is almost always 
accompanied by abnormality of MSH6, and  
MLH1 with an abnormality of PMS2 . This 
heterodimeric binding of the proteins acts 
as a very useful confirmatory finding. 
The antigenic epitopes for the four anti-
MMR antibodies are particularly fixation-
sensitive and immunostaining patterns 
should only be assessed in well-fixed 
regions of the tissue section, for example  
where the adjacent normal epithelium or 
the intra- or peri-tumoural lymphoid cells or 
stromal cells such as fibroblasts show 
clear, strong nuclear immunopositivity for 
all four of the MMR proteins. Any poorly 
fixed central parts of the tumour should not 
be taken into consideration. 
 
Control Tissue 
Appendix (Fig 1 &2) or normal colon (Fig 3) 
are appropriate control tissues to use for 
immunohistochemistry for all 4 MMR 
proteins and this should show: 
i. Strong nuclear staining of the epithelium 
at the base and lower half of the crypts (Fig 
1-3), with fading of nuclear staining 
intensity in the middle and upper third of 
the crypts (Fig 2 & 3), to negative or weak 
staining of  epithelial nuclei at the luminal 
surface. 
ii. There should be very strong staining of 
lymphoid follicles (Fig 1). 
Tonsil has been used as a control tissue, 
but this tends to show too strong a nuclear 
staining signal in both the lymphoid follicles 
and the overlying squamous  epithelium 
(Fig 4), making it difficult to gauge the 
sensitivity of the stain. Appendix is 
therefore recommended as the better 
tissue to use for control purposes. 
 
Interpretation & Reporting guidelines 
1. We recommend reporting MMR IHC 
findings in tumours as either: 
a) Normal: Demonstrating strong 
immunopositivity of the tumour cell nuclei 
for all four MMR proteins, similar in 
staining intensity to that of the adjacent 
normal epithelium or intra-tumoural 
lymphoid cells or stromal cells. 
b) Negative: Showing complete loss of 
staining, relative to the strongly intensive 
immunopositivity of the adjacent normal 
epithelium or intra-tumoural lymphoid cells 
or stromal cells. 
c) Patchy/weak: Staining intensity of one or 
two of the MMR proteins is either weak or 
patchy in the tumour cell nuclei, compared 
to adjacent normal epithelium or intra-
tumoural lymphoid cells or stromal cells, 
that show strong nuclear positivity in a well 
fixed region of the tumour. 
This patchy/weak staining may often be 
seen in the cytoplasm rather than the 
nucleus, whereas, the adjacent normal 
epithelium or intra-tumoural activated 
lymphocytes or stromal cells show the 
usual pattern of strong nuclear 
immunopositivity for the MMR protein (due 
to the expression of the wild-type allele).  
This suggests that destabilisation of the 
MMR protein complexes has occurred and 
the proteins are no longer bound to the 
nuclear DNA.   
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Reports 
Reports should conclude with a statement 
that evidence of abnormal MMR 
immunohistochemical expression has, or 
has not, been found.  If abnormal MMR 
expression has been found the comment is 
made that this is compatible with, but not 
necessarily diagnostic of Lynch / HNPCC, 
and that, if not already organised, referral of 
the individual and their family should be 
made to clinical genetic services.  
Because abnormality of MMR protein 
expression is evidence in itself of loss of 
MMR function in that tumour, then a 
comment may also be made that MSI 
studies are not needed.  
A small minority of tumours may show 
unusual combinations of abnormal MMR 
protein expression, e.g. loss of both MSH2 
and MLH1, or three out of the four proteins 
(MSH2, MLH1, MSH6 & PMS2).  It is 
suggested that the IHC be repeated and 
then a clinico-pathological review of the 
case be carried out, as necessary, to decide 
whether to proceed with e.g. testing of other 
tumours from the same individual or family, 
or proceeding directly with mutation 
detection. 
 
Discussion 
Abnormality of MMR protein expression is 
not in itself necessarily diagnostic of Lynch / 
HNPCC, as around 15% of sporadic colon 
cancers show loss of MLH1 staining due to 
acquired promoter methylation, and some 
sporadic colorectal tumours will also lose 
MSH2, MSH6 or PMS2. While there is 
evidence that abnormal MMR expression in 
rectal cancers is more predictive of Lynch 
Syndrome, it is by no means an absolute.  
Where available and appropriate, it can be 
suggested that testing for the BRAF V600E 
mutation is a way of distinguishing a 
proportion of MLH1-negative tumours as 
sporadic.  It is important to appreciate that 
full interpretation of MMR immunostaining 
can only be made in the wider context of 
e.g. family history data and mutation 
detection studies, preferably by means of a 
multidisciplinary team including geneticists.  
Only then can a diagnosis of Lynch / HNPCC 
syndrome can be made. If abnormal MMR 
expression has not been found the covering 
statement is made that MSI studies should 
be carried out to include or exclude MMR 
functional abnormality in the tumour 
(because of the proportion of tumours with 
MSI that do not exhibit an abnormality of 
MMR protein expression). 
 
The use of scoring systems that attempt to 
quantify the extent of immunopositivity are 
considered to be inappropriate as variation 
in extent of immunostaining reflects 
variation in fixation of the epitope or effects 
of epitope retrieval, which are not biological 
phenomena. Geneticists wish to know if 
there is an abnormal expression pattern 
that reflects genetic abnormalities, and this 
requires identification of a well fixed part of 
the tumour where the intensity of 
immunopositivity in tumour cell nuclei can 
be directly compared with the strong 
nuclear staining intensity in well fixed 
adjacent normal epithelium or lymphoid 
cells or stromal cells. Artefactually distorted 
staining patterns due to poor fixation 
(affecting both stromal cells as well as 
tumour cells) in central parts of the tumour 
are irrelevant.  It should be borne in mind 
that geneticists may use the in vivo 
expression pattern of MMR proteins to 
interpret mutations of uncertain 
significance, and that both false-negative 
and false-positive staining (or interpretation) 
may potentially cause misinterpretation of 
DNA sequence findings.  This could result in 
a mutation being interpreted as pathogenic 
when it is, in fact, neutral in effect, and thus 
result in inappropriate predictive genetic 
testing being offered to the family.  Hence, 
care is needed in both staining and 
interpretation. 
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